Loading
A phase 2 trial of Rituximab, Filgrastim and Granisetron in Leukaemia and Mantle cell lymphoma, run by Stanford University, completed.
Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD is a phase 2 interventional study registered as NCT00186628 by Stanford University, with 36 participants recorded, started 2005-06 and reaching its primary completion in 2010-11. Interventions recorded: Total lymphoid irradiation, Rituximab, Anti-thymoglobulin, rabbit (ATG, rabbit ATG), Cyclosporine, Mycophenylate mofetil, Filgrastim, Granisetron, Solumedrol, Acetaminophen, Diphenhydramine, Hydrocortisone. Conditions recorded: Leukemia, Mast-Cell, Mantle-cell Lymphoma.
Linked to the drug Granisetron because the registry names it among its interventions and Leukaemia and Mantle cell lymphoma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
36 enrolled.
95% CI 6 to 34; Figures from the ClinicalTrials.gov results section (first posted 2017-11-28), not from a publication
Source95% CI 57 to 94; Figures from the ClinicalTrials.gov results section (first posted 2017-11-28), not from a publication · 95% CI 48 to 99
SourceThe full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rituximab, Mantle cell lymphoma and the tag pipeline.
Shares Rituximab, Leukaemia (all types) and the tag pipeline.
Shares Filgrastim (G-CSF) and the tag pipeline.
Shares Filgrastim (G-CSF), Leukaemia (all types) and the tag pipeline.
Shares Filgrastim (G-CSF) and the tag pipeline.
Shares Filgrastim (G-CSF) and the tag pipeline.
Shares Filgrastim (G-CSF), Rituximab and the tag pipeline.
Shares Filgrastim (G-CSF) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/